Volume 24, Issue 4, Pages 291-295 (December 2017) Two year follow-up of Crohn’s patients substituted to certolizumab anti-TNFa therapy: SAVANT 2 Andrew Motlis, Moheb Boktor, Paul Jordan, Urska Cvek, Marjan Trutschl, J. Steven Alexander Pathophysiology Volume 24, Issue 4, Pages 291-295 (December 2017) DOI: 10.1016/j.pathophys.2017.07.004 Copyright © 2017 Elsevier B.V. Terms and Conditions
Fig. 1 Study design. Illustration showing that full induction was required for inclusion. Patients who were lost to follow up were not included in the failure group. Pathophysiology 2017 24, 291-295DOI: (10.1016/j.pathophys.2017.07.004) Copyright © 2017 Elsevier B.V. Terms and Conditions
Fig. 2 Graph illustrating the cumulative proportion of patients who lost maintained and lost responsiveness over the 12 and 24 month phases of the SAVANT 1 and SAVANT 2 study periods. Pathophysiology 2017 24, 291-295DOI: (10.1016/j.pathophys.2017.07.004) Copyright © 2017 Elsevier B.V. Terms and Conditions